Core Insights - DarioHealth Corp. has launched five new contracts with self-insured employers, covering 107,000 lives, which reinforces its B2B2C momentum and recurring revenue growth [1][2] - The company's digital health solutions have demonstrated significant results, including a 23% reduction in hospitalizations, a 9% reduction in healthcare utilization, and a $5,000 reduction in employer costs per user [1] - Dario's pipeline of commercial opportunities has increased to $67 million, with expectations to sign approximately 40 new clients by the end of 2025, representing a 35% increase over 2024 [2] Company Overview - DarioHealth Corp. is a leader in the digital health market, focusing on chronic condition management through a user-centric, multi-chronic condition digital therapeutics platform [3] - The platform provides personalized interventions driven by data analytics and coaching for conditions such as diabetes, hypertension, and weight management [3][4] Product Efficacy - Dario's solutions have shown measurable improvements in health outcomes: a 1.4% reduction in eHbA1c for diabetes management, a 10% reduction in BMI for prediabetes, and 38% of users reducing blood pressure by one stage for hypertension [6]

Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 5, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 12th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and ...

Core Insights - The United Kingdom telehealth market was valued at USD 21.56 Billion in 2024 and is projected to grow at a CAGR of 12.10%, reaching USD 67.56 Billion by 2034, driven by increased internet access and smartphone penetration [2][10] - Strong policy support from the NHS and the UK government is facilitating the adoption of telehealth services, ensuring funding and integration within public healthcare frameworks [2] Market Growth Drivers - The UK government announced an investment of up to EUR 600 million (USD 764 million) for a centralized Health Data Research Service, aimed at enhancing data access for researchers and accelerating clinical trials, which is expected to significantly boost telehealth market growth [4] - Rising demand for remote inpatient care and AI-driven solutions, such as Teladoc's AI-powered Virtual Sitter, are enhancing patient safety and care efficiency, contributing to market value growth [5] - User-centric telehealth platforms, like Doctorsa's global telehealth platform, are addressing increasing wait times for GP appointments and improving patient satisfaction, thereby driving market development [5] Market Trends - AI-powered tools for women's health, such as Moody's mental health tool, are expanding the telehealth market by providing personalized care solutions [8] - Investment in virtual wards, exemplified by West Suffolk NHS Foundation Trust's tender for remote patient monitoring services, is expected to enhance clinical outcomes and operational efficiency [8] - Digital therapeutics are gaining traction, offering validated software-based interventions for chronic conditions, supported by NHS initiatives [8] Market Segmentation - The services segment is anticipated to lead the market due to its role in enabling seamless virtual care delivery, particularly in managing chronic diseases and elderly care [8] - England is expected to dominate the market, supported by a robust NHS digital infrastructure and a high urban population, while Scotland, Wales, and Northern Ireland are progressing at varying rates [8] Key Players - Major companies in the UK telehealth market include Doctor Care Anywhere, Teladoc Health, Livi, Babylon Health, Medicspot, Push Doctor, eConsult Health, Cisco Systems Inc., and Codal [7][19]

Core Insights - Quantum eMotion Corp. has converted $350,000 in debt into equity and made an additional investment of $350,000 in Greybox Solutions Inc., becoming the second-largest shareholder in the company [1][2] - This strategic investment reflects Quantum eMotion's confidence in Greybox's growth in the Remote Care Management and Digital Therapeutics sector, particularly following the launch of the TakeCareTM platform [2][4] - The digital therapeutics market is projected to grow at over 20% CAGR globally, indicating significant potential for both companies [4] Company Overview - Greybox Solutions is a Montreal-based health technology company focused on innovative software development aimed at improving patient care and addressing healthcare system challenges [5] - The TakeCareTM platform is designed to enhance the relationship between patients and healthcare teams, positioning Greybox as a leader in digital health [5] - Quantum eMotion specializes in cybersecurity solutions, leveraging its patented Quantum Random Number Generator technology to provide enhanced protection for critical systems [6][7] Strategic Partnership - The partnership between Quantum eMotion and Greybox Solutions is strengthened by Quantum's Sentry-Q cybersecurity platform, which secures the TakeCareTM platform [3][4] - The appointment of Quantum eMotion's CEO, Francis Bellido, to Greybox's Board of Directors is expected to enhance strategic alignment and access to a broader healthcare network [4] - This collaboration emphasizes the importance of building a trusted, quantum-safe infrastructure for the future of digital therapeutics [4]

Core Insights - Quantum eMotion Corp. announced the deployment of its TakeCareTM digital health platform in Quebec, in partnership with Greybox Solutions, as part of a $4.9 million initiative to modernize rehabilitation services across Canada [1][2]. Company Overview - Greybox Solutions is a Montreal-based health technology company focused on innovative software development aimed at improving patient lives and addressing healthcare system challenges [3]. - Quantum eMotion Corp. specializes in cybersecurity solutions, leveraging its patented Quantum Random Number Generator to enhance protection for connected devices and critical systems [4]. Product Features - TakeCareTM introduces intelligent digital care pathways designed to reduce intake delays, eliminate redundant clinical assessments, and empower patients with real-time recovery plans [6]. - The platform emphasizes securing patient data, ensuring treatment integrity, and enhancing platform reliability through advanced cybersecurity measures [7]. Strategic Partnerships - The deployment of TakeCareTM follows a revenue-sharing agreement between Quantum eMotion and Greybox Solutions to co-secure digital health applications, setting a new benchmark for patient-centric digital therapeutics [2].

Core Insights - Medidata is advancing the life sciences industry through innovative, AI-powered solutions and a focus on patient, data, and study experiences [1][5][6] Group 1: Innovation and Partnerships - Medidata has launched the Site Insights Program to enhance site engagement and technology compliance in research [3] - The company has partnered with Cogstate to develop a comprehensive CNS trial experience, optimizing endpoint data quality [4] - Collaborations with Click Therapeutics aim to support patients beyond clinical trials with software-enhanced drugs [4][5] Group 2: Market Leadership - Medidata secured new enterprise agreements with a large pharmaceutical company, two top 10 biopharma manufacturers, and ICON, reinforcing its position as a trusted partner in clinical trials [5] - The company continues to set industry standards in clinical trial innovation, leveraging AI and machine learning to accelerate drug development [5] Group 3: Recognition and Awards - Medidata's Clinical Data Studio was recognized for improving data quality and accelerating study timelines, earning accolades from the Summit for Clinical Ops Executives [6] - The company was inducted into the Digital Health New York Hall of Fame, highlighting its commitment to innovation [6] - Medidata received the 2025 MedTech Breakthrough Award for Best Clinical Trial Technology Solution Provider due to its collaboration with Cogstate [6] Group 4: Leadership Strengthening - Medidata has enhanced its leadership team with new executive appointments and promotions to drive patient-centered innovation [7]

Industry Overview - The medical instruments industry is experiencing a transformative phase driven by the rapid adoption of generative artificial intelligence (genAI) and digital therapeutics, which are expected to significantly impact the healthcare sector [1] - Since early 2023, there has been mass adoption of AI and the Internet of Medical Things in digital healthcare options across hospitals and healthcare settings [1] Generative AI Impact - GenAI is demonstrating its capabilities in various healthcare fields, including administrative tasks, technological discovery, and clinical trials, by analyzing complex genetic and molecular data [2] - The technology is anticipated to enhance predictive treatment options and smart hospital systems [2] Investment Opportunities - It is advisable to invest in stocks from the Zacks-defined Medical Instrument industry that have a favorable Zacks Rank, with five selected stocks showing double-digit returns amid market volatility [3][4] Selected Stocks - **DexCom Inc. (DXCM)**: Benefiting from strong performance in the Sensor segment, with expected revenue and earnings growth rates of 14.3% and 23.2% respectively for the current year [7][8] - **IDEXX Laboratories Inc. (IDXX)**: Demonstrating robust strategic execution with expected revenue and earnings growth rates of 5.8% and 14% respectively for the current year [9][11] - **NeuroPace Inc. (NPCE)**: Focused on developing a brain-responsive neuromodulation system for treating drug-resistant focal epilepsy, with expected revenue and earnings growth rates of 18.1% and 15.1% respectively for the current year [12][13] - **Fresenius Medical Care AG (FMS)**: Benefiting from strong organic growth and operational improvements, with expected revenue and earnings growth rates of 1.6% and 28.3% respectively for the current year [14][15] - **ClearPoint Neuro Inc. (CLPT)**: Specializing in minimally invasive surgical procedures in the brain, with expected revenue and earnings growth rates of 24.1% and 11.4% respectively for the current year [16][17]

Core Viewpoint - DarioHealth Corp. will release its financial results for the first quarter of 2025 on May 14, 2025, and will host a conference call to discuss these results [1][2]. Group 1: Conference Call Details - The conference call is scheduled for May 14, 2025, at 8:30 a.m. Eastern Time [3]. - Participants can join via a domestic dial-in number (1-800-717-1738) or an international number (1-646-307-1865) [3]. - A replay of the call will be available approximately two hours after the event until May 28, 2025 [3]. Group 2: Company Overview - DarioHealth Corp. is a leader in the digital health market, focusing on chronic condition management through a user-centric digital therapeutics platform [4]. - The platform provides personalized interventions for conditions such as diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health [4]. - DarioHealth's approach aims to empower users to make sustainable lifestyle changes, enhancing user satisfaction and retention [5]. Group 3: Market Reach - DarioHealth offers its solutions globally to health plans, self-insured employers, care providers, and consumers [6].